Last Updated : May 21, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name Sort ascending | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| TBC | filgotinib | Arthritis, Rheumatoid | Withdrawn | |||
| Dificid | Fidaxomicin | Clostridium difficile infection | Do not list at the submitted price | Complete | ||
| Dificid | fidaxomicin | Clostridium difficile infection | Active | |||
| Beqvez | fidanacogene elaparvovec | Hemophilia B | Reimburse with clinical criteria and/or conditions | Active | ||
| Toviaz | Fesoterodine fumarate | Overactive bladder | List in a similar manner | Complete | ||
| TBC | ferumoxytol | Iron deficiency anemia | Withdrawn | |||
| Ferinject | ferric carboxymaltose | Iron deficiency anemia | Received | |||
| Ferinject | ferric carboxymaltose | Iron deficiency in adult patients with heart failure | Received | |||
| Abstral | Fentanyl citrate | Pain, breakthrough cancer pain | Do not list | Complete | ||
| Onsolis | Fentanyl Citrate | Pain, breakthrough cancer pain | Do not list | Complete |
Last Updated : May 21, 2024